IQVIA Holdings Inc. $IQV Shares Sold by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 53.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,296 shares of the medical research company’s stock after selling 29,966 shares during the period. Kornitzer Capital Management Inc. KS’s holdings in IQVIA were worth $4,995,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in IQV. Verdence Capital Advisors LLC acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $3,612,000. Amundi raised its position in IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock worth $210,722,000 after acquiring an additional 405,250 shares during the period. Diversified Trust Co grew its position in shares of IQVIA by 57.2% in the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock valued at $8,087,000 after purchasing an additional 15,487 shares during the period. Act Two Investors LLC purchased a new stake in shares of IQVIA during the second quarter worth about $26,528,000. Finally, Oregon Public Employees Retirement Fund raised its position in shares of IQVIA by 37.1% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 19,463 shares of the medical research company’s stock worth $3,697,000 after purchasing an additional 5,271 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

IQVIA stock opened at $241.03 on Wednesday. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The firm has a market cap of $41.05 billion, a PE ratio of 33.06, a price-to-earnings-growth ratio of 2.44 and a beta of 1.36. The company’s 50 day moving average is $230.03 and its two-hundred day moving average is $207.28.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. During the same period last year, the firm earned $2.84 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on IQV shares. Robert W. Baird set a $258.00 price objective on IQVIA and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Evercore ISI lifted their price target on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a report on Wednesday, October 8th. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Truist Financial lifted their price target on shares of IQVIA from $265.00 to $290.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Mizuho set a $266.00 price objective on shares of IQVIA in a report on Friday, January 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $251.06.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.